LEAVE Safe With DOACs

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
Given the risks associated with direct oral anticoagulants (DOACs) and the lack of defined pathways for patients prescribed this class of medications, the study intervention has the potential for an enormous impact in preventing medication errors and improving the quality of care transition, patient knowledge, and adherence with DOAC therapy.
Epistemonikos ID: 9af799b706262fc54ca713e2d80c101618c421f7
First added on: May 22, 2024